Hanoi is the north’s largest healthcare center, with central-level hospitals, research institutes and the country’s densest network of pharmaceutical and medical-device distributors. For foreign investors joining the healthcare supply chain here — as manufacturers, importers or distributors — the distinctive barrier is that products directly affect human health: licenses and standards are preconditions, not nice-to-haves. This guide offers a practical framework: supplier segmentation by product group, the licensing regime in force, supplier auditing, and hedging distinctive risks such as supply breaks, counterfeits and tender volatility.
1. Three product groups, three requirement sets
The healthcare chain splits into three groups with different regulatory intensity. Pharmaceuticals face the highest bar: good manufacturing practice (GMP) is the widely required standard for drug plants, and pharmaceutical distribution equally demands compliant warehousing and transport (GDP is the common commercial standard). Medical devices are managed by risk class, from low-risk type A to high-risk categories requiring marketing authorization. Consumables (gloves, masks, test kits, syringes): high volume and price-competitive, yet still needing full quality dossiers because they touch patients directly. The common thread: every link needs clear legal paperwork before price is even discussed — investors should pin down their product group first so the right requirement set applies.
2. Qualifying in a regulated market: the licensing spine
For medical devices, Decree 98/2021/ND-CP (8 November 2021, still in force) is the governing framework: risk-based classification of devices and marketing authorization rules. Circular 24/2026/TT-BYT (30 June 2026, effective 1 July 2026) amends the detailed guidance on the decree, including risk determination and management measures — investors must track these updates. For pharmaceuticals, GMP compliance is the broadly required standard for manufacturing sites, while distributors need qualified warehouse and transport systems. Plants generating wastewater, emissions or waste, including hazardous medical waste, fall under the Law on Environmental Protection 72/2020/QH14 with licensing per Decree 08/2022/ND-CP. When vetting suppliers, verifying that marketing authorizations are current and correctly scoped to the product type is a non-negotiable step.
3. Where suppliers sit in Hanoi
Four channels. First, authorized distributors of major pharma and device brands — the safest on origin, least flexible on price. Second, industrial parks and clusters hosting operating drug and device plants; the park management boards are useful longlist sources. Third, pharma and medical-device associations plus specialty expos — where manufacturers are met and regulatory updates surface. Fourth, public-hospital tender channels: supplying the public sector demands tender-dossier capability and scoring-criteria compliance; reviewing past award results is also an indirect way to assess the real capability of rivals and potential partners. A standing warning: never buy drugs or devices through intermediaries of unclear origin — counterfeit risk in healthcare carries not only economic loss but serious legal liability.
4. Auditing healthcare suppliers
Assess: legal standing (current marketing authorizations correctly scoped; valid GMP/GDP certification for pharma manufacturing and distribution sites); warehousing and logistics (cold chain, temperature-controlled storage, handling procedures — critical for vaccines and biologicals); quality management (incoming inspection, nonconforming-product handling, recalls); traceability and anti-counterfeit measures (barcodes, seals, complete lot dossiers); financial capacity and supply track record (past tender wins, hospital customer lists). Re-audit annually, trigger ad-hoc audits on quality complaints, and contractually require suppliers to notify you immediately of license changes or counterfeits discovered in their own channels.
5. Hedging the distinctive risks
Input breaks: many pharma inputs and device components are imported, so keep at least two sources for strategic inputs with safety stock sized to real import lead times plus congestion margins. Counterfeits: contracts should make suppliers fully liable if fakes are found in their lots, with rights to unannounced warehouse inspections. Tender volatility: criteria and winning prices shift each cycle, so never concentrate revenue on a few public tenders — diversify across private hospitals, clinics and pharmacies. Regulatory drift: reclassification or re-registration changes (as in Circular 24/2026/TT-BYT) can force dossier supplements for products already on the market — monitor new instruments continuously and assign regulatory ownership. A practical 90-day sequence: days 1–30 pin down the product group and licensing map, build the longlist from the four channels and review all applicable instruments; days 31–60 audit strategic candidates on site — authorizations, GMP/GDP, cold chain, traceability — and run trial orders with independent testing; days 61–90 sign framework contracts with quality, anti-counterfeit, license-change notification and recall clauses, approve the backup list, and set the periodic audit calendar plus a regulatory watch routine. This framework lets investors exploit Hanoi’s healthcare centrality while withstanding the strictest compliance bar among consumer industries.
Frequently asked questions
1. What does Decree 98/2021/ND-CP regulate for medical devices?
It is the governing framework still in force: risk-based classification of medical devices and marketing authorization rules. Circular 24/2026/TT-BYT (effective 1 July 2026) amends the detailed guidance, including risk determination and management measures.
2. Why avoid intermediaries of unclear origin for drugs and devices?
Counterfeit risk in healthcare brings not only economic loss but serious legal liability, and directly endangers patients. Buy through authorized distributors or manufacturers with clear marketing authorizations.
3. What should pharma distributor warehouse audits check?
Cold chain, temperature-controlled storage, compliant handling and transport procedures (GDP is the common commercial standard) — especially for vaccines and temperature-sensitive biologicals.
4. How should the circulation registration number be checked when buying medical devices for a hospital or clinic?
Under Decree 98/2021 and Circular 24/2026/TT-BYT, a medical device must be classified into the correct risk class and hold the corresponding circulation registration number or import license before being put into use. When vetting a supplier, request the registration dossier of the exact model and configuration offered, and cross-check it against the regulator’s published records — devices “borrowing” the registration of another model are a common defect of unofficial distribution channels.
5. Where does the Hanoi healthcare supply chain usually break, and how is it prevented?
Breaks typically occur at imported goods dependent on a single distributor and at short-shelf-life consumables ordered on long cycles. Prevention means tiering inventory by criticality, keeping dual sources for essential consumables, and auditing the distributor’s warehouse conditions against GDP practice, because medical supplies damaged by poor storage often only reveal themselves once already in use.